Attainment of low-density lipoprotein cholesterol goals in patients treated with combination therapy: a retrospective cohort study in primary care
Abstract
Background The attainment of low-density lipoprotein cholesterol (LDL-C) therapeutic goals in real-world settings among patients receiving combination lipid-lowering therapy (LLT, statins plus non-statins) is not well characterised. Objective To evaluate LDL-C levels and LDL-C goal attainment in patients treated with combination LLT in real-world primary care settings. Methods A retrospective cohort study of patients treated with combination LLT. Data were drawn from general practitioner electronic medical records across Australia from 2013 to 2019. The on-treatment goal for LDL-C was Results The cohort analysed included 9,173 individuals treated with combination LLT. The mean age was 65.8 years (standard deviation [SD] 11.5), 60.1% were males, and 56.7% had at least one cardiovascular risk factor. The median on-treatment LDL-C was 2.1 mmol/L (IQR 1.6-2.8), and overall 45.4% of the cohort met LDL-C goals, with individuals on fixed-dose combination of statins plus ezetimibe having the highest rates of achievement (49.8%). In multivariable logistic regression analyses, factors associated with LDL-C goal achievement were male sex (odds ratio [OR] 1.4, 95% confidence interval [CI] 1.3-1.6, p 80 years (OR 4.2, 95% CI 1.5 - 6.6, p = 0.006), and a history of T2DM (OR 1.7; 95% CI 1.5-1.9, p Conclusions More than half of Australians on combination LLT did not achieve LDL-C goals. Urgent measures are needed to address this gap in clinical practice to minimise negative health outcomes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the clinical setting, inadequate treatment to achieve LDL-C targets is a persistent issue, with physician inertia contributing to suboptimal dosing or utilisation of LLMs and their combinations.
“In the clinical setting, inadequate treatment to achieve LDL-C targets is a persistent issue, with physician inertia contributing to suboptimal dosing or utilisation of LLMs and their combinations.74, 75, 76, 77, 78, 79”
From Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis (2025) · cites this paper as [76]
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Impact of Lipids on Cardiovascular Health
Ference, B. A., Graham, I., Tokgozoglu, L., & Catapano, A. L. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.06.046 · Cited by 511 · see citing works
Teramoto, T., Uno, K., Miyoshi, I., Khan, I., Gorcyca, K., Sanchez, R. J., Yoshida, S., Mawatari, K., Masaki, T., Arai, H., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.001 · Cited by 71 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Barrios, V., Pintó, X., Escobar, C., Varona, J. F., & Gámez, J. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093187 · Cited by 42 · see citing works
Interventions to improve adherence to lipid-lowering drugs: a systematic review and meta-analysis
Yow, D. K. W., Ang, W. J., Yap, H. J., Ito, S., Liu, J., Ko, J., Tan, D. S.-Y., Lorenzatti, A., & Ang, C.-S. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103270 · Cited by 5 · see citing works
- Authors
- Marquina, C., Talic, S., Zomer, E., Vargas-Torres, S., Petrova, M., Wolfe, R., Abushanab, D., Lybrand, S., Thomson, D., Stratton, G., Ofori-Asenso, R., Liew, D., & Ademi, Z.
- Affiliations
- Monash University (AU)
- Hamad Medical Corporation (QA)
- Amgen (Germany) (DE)
- Amgen (Australia) (AU)
- IQVIA (United Kingdom) (GB)
- Corresponding author
- Ademi, Zanfina
- ORCID
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 16
- Issue
- 4
- Pages
- 498-507
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W4280626828
- Cited by
- 9
- References
- 4
- Citations by year
- 2025: 4 · 2024: 1 · 2023: 3 · 2022: 1
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of clinical lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AMGC
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- LDL cholesterol, LDL-C goal attainment, combination lipid-lowering therapy, statins, ezetimibe, fixed-dose combination, primary care, cardiovascular risk, type 2 diabetes, coronary artery disease, older adults, sex differences, Australian guidelines
- MeSH terms
- Aged, Australia, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Primary Health Care, Retrospective Studies, Cohort Studies, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review